UB's Jacobs School of Medicine and Biomedical Sciences is among 72 sites nationwide that are recruiting patients for a 12-week, randomized, placebo-controlled drug trial for the first treatment designed to benefit patients with mild-to-moderate Lewy body dementia (LBD).
After Alzheimer’s disease, LBD and related Parkinson’s disease dementia (PDD) are some of the most common types of dementia affecting older adults; but they are severely understudied.
While LBD patients are often prescribed medications that treat psychosis and Alzheimer’s disease, there are no medications designed specifically to treat LBD. Eli Lilly and Company has launched a clinical trial in hopes of changing that.
“Participating in this trial could help push this drug more quickly through the pipeline,” says Kinga Szigeti, MD, PhD, associate professor of neurology, who is principal investigator at UB.